Cover Image
市場調查報告書

EpiCast Report:肌肉萎縮性側索硬化症(俗稱漸凍人)(ALS)的流行病學的預測

EpiCast Report: Amyotrophic Lateral Sclerosis - Epidemiology Forecast to 2023

出版商 GlobalData 商品編碼 301139
出版日期 內容資訊 英文 38 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:肌肉萎縮性側索硬化症(俗稱漸凍人)(ALS)的流行病學的預測 EpiCast Report: Amyotrophic Lateral Sclerosis - Epidemiology Forecast to 2023
出版日期: 2014年05月01日 內容資訊: 英文 38 Pages
簡介

肌肉萎縮性側索硬化症(ALS)是稱作路格里克氏病的進行性神經退化性疾病,對腦和脊椎的神經細胞有不良影響。ALS對身體功能造成嚴重影響,在初期階段,產生肌肉抽搐和腕部、腿部的弱化,口齒不清的症狀。之後,ALS患者階段性喪失對移動、會話、用餐、呼吸必要肌肉的控制能力,最後導致死亡。身體能力的階段性退化這個症狀,成為患者和看護者雙方,以及社會整體而言的沉重負擔。全球主要7個國家的ALS確診的患病人數,從2013年的32,698人,預計至2023年增加到37,122人(增加率13.5%)。各國中美國有最大的患者數,其次是日本。

本報告提供全球主要7個國家(美國、法國、德國、義大利、西班牙、英國、日本)的肌肉萎縮性側索硬化症(ALS)的發病情形和今後預測相關分析、疾病的特徵(風險要素和主要的共生病症等等)全球各國的趨勢、目前患病者的發病情形、今後10年的發病、患病數量的預測值等調查評估,並將其結果依為您概述為以下內容。

第1章 目錄

第2章 簡介

  • 概要
  • 近日出版的相關調查

第3章 流行病學

  • 疾病的背景
  • 風險要素和共生病症
  • 全世界的趨勢
    • 美國
    • 歐洲5個國家
    • 日本
  • 預測手法
    • 利用之資訊來源
    • 未利用之資訊來源
    • 預測的前提條件與手法:
  • 肌肉萎縮性側索硬化症(ALS)的流行病學預測(今後11年份)
    • 確診的患病人數
    • 確診的患病人數(各年齡)
    • 確診的患病人數(性別)
    • 確診的患病人數(已調整年齡)
  • 議論
    • 流行病學性的預測相關結論
    • 分析的限制
    • 分析的優勢

第4章 附錄

圖表一覽

目錄
Product Code: GDHCER063

Amyotrophic lateral sclerosis (ALS), often referred to as "Lou Gehrig's Disease," is a rare, but fatal, progressive neurodegenerative disease that affects the nerve cells in the brain and the spinal cord. ALS severely impacts physical functioning and initially presents with muscle twitching, weakness in an arm or leg, or with slurring of speech. Eventually, people with ALS lose their ability to control the muscles needed to move, speak, eat, and breathe, which ultimately leads to death. The progressively degenerative course of the condition is a great burden for both patients and caregivers, as well as for society.

GlobalData epidemiologists forecast that the diagnosed prevalent cases of ALS in the 7MM will grow by 13.5% over the next decade, from 32,698 diagnosed prevalent cases in 2013 to 37,122 diagnosed prevalent cases in 2023. Throughout the forecast period, the US will have the highest numbers of diagnosed prevalent cases of ALS, followed by Japan.

To develop the epidemiological forecast for the diagnosed prevalent cases of ALS in the 7MM, GlobalData epidemiologists obtained the diagnosed prevalence data for ALS from peer-reviewed journals and population-based studies in the respective markets and used a consistent methodology to ensure comparability of the results. A major strength of GlobalData's epidemiological analysis is the use of country-specific studies that provided the diagnosed prevalence of ALS using uniform diagnostic criteria based on the El Escorial criteria or the International Classification of Diseases, Ninth Revision (ICD-9), criteria (ICD-9 code for ALS = 335.2), to allow for a meaningful comparison of the diagnosed prevalent cases of ALS in these markets. Furthermore, the diagnosed prevalent cases of ALS in each of the 7MM were further segmented by age and sex in order to provide a more detailed analysis of the patient population.

Scope

  • The Amyotrophic lateral sclerosis (ALS) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for ALS in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of ALS segmented by age (=40 years) and sex in these markets.
  • The ALS epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global ALS market.
  • Quantify patient populations in the global ALS market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for ALS therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Upcoming Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
    • 3.3.1. US
    • 3.3.2. 5EU
    • 3.3.3. Japan
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods
  • 3.5. Epidemiological Forecast for Amyotrophic Lateral Sclerosis (2013-2023)
    • 3.5.1. Diagnosed Prevalent Cases of ALS
    • 3.5.2. Age-Specific Diagnosed Prevalent Cases of ALS
    • 3.5.3. Sex-Specific Diagnosed Prevalent Cases of ALS
    • 3.5.4. Age-Standardized Diagnosed Prevalence of ALS
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Epidemiology and Health Policy
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for ALS
  • Table 2: Incidence (Cases per 100,000 Population) of ALS in the US, as Reported in Epidemiological Studies
  • Table 3: Prevalence (Cases per 100,000 Population) of ALS in the US, as Reported in Epidemiological Studies
  • Table 4: Incidence (Cases per 100,000 Population) of ALS in the European Markets, as Reported in Epidemiological Studies
  • Table 5: Prevalence (Cases per 100,000 Population) of ALS in the European Markets, as Reported in Epidemiological Studies
  • Table 6: El Escorial Diagnostic Criteria for ALS
  • Table 7: 7MM, Sources of Diagnosed Prevalence Data Used to Forecast the Diagnosed Prevalent Cases of ALS
  • Table 8: 7MM, Diagnosed Prevalent Cases of ALS, Age ≥40 Years, Both Sexes, N, 2013-2023
  • Table 9: 7MM, Diagnosed Prevalent Cases of ALS, by Age, Both Sexes, N, (Row %), 2013
  • Table 10: 7MM, Diagnosed Prevalent Cases of ALS, by Sex, Age ≥40 years, N (Row %), 2013

List of Figures

  • Figure 1: 7MM, Diagnosed Prevalent Cases of ALS, Age ≥40 Years, Both Sexes, N, 2013-2023
  • Figure 2: 7MM, Diagnosed Prevalent Cases of ALS, by Age, Both Sexes, N, 2013
  • Figure 3: 7MM, Diagnosed Prevalent Cases of ALS, by Sex, Age ≥40 Years, N, 2013
  • Figure 4: 7MM, Age-Standardized Diagnosed Prevalence (%) of ALS, Age ≥40 Years, 2013
Back to Top